Evidence map›Paper›PMID 27313466›Full record

ArticleOncoTargets and therapy2016

Clinicopathological significance of claudin 4 expression in gastric carcinoma: a systematic review and meta-analysis.

Xiaowan Chen, Junhua Zhao, Ailin Li, Peng Gao, Jingxu Sun, Yongxi Song, Jingjing Liu, Ping Chen, Zhenning Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Claudins as biomarkers of differential diagnosis and prognosis of tumors.Journal of cancer research and clinical oncology · 2021
    Review
  10. Article
  11. Targeting claudins in cancer: diagnosis, prognosis and therapy.American journal of cancer research · 2021
    Review
  12. Article
  13. Article
  14. Article
  15. Antiangiogenic effects of oridonin.BMC complementary and alternative medicine · 2017
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Xiaowan ChenDepartment of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, People's Republic of China.
Junhua ZhaoDepartment of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, People's Republic of China.
Ailin LiDepartment of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, People's Republic of China; Department of Radiation Oncology, First Hospital of China Medical University, Shenyang, People's Republic of China.
Peng GaoDepartment of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, People's Republic of China.
Jingxu SunDepartment of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, People's Republic of China.
Yongxi SongDepartment of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, People's Republic of China.
Jingjing LiuDepartment of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, People's Republic of China.
Ping ChenDepartment of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, People's Republic of China.
Zhenning WangDepartment of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, People's Republic of China.
First Hospital of China Medical University · CNAnesthesiology and Surgical Oncology Research Group · USChina Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognostic significance of claudin 4 (CLDN4) in patients with gastric cancer (GC) is controversial. This meta-analysis aims to assess the correlation between CLDN4 expression and clinicopathological characteristics and assess the prognostic significance of CLDN4 in GC.

methodsWe searched the PubMed and Embase databases. We performed the meta-analysis with odds ratio (OR), hazard ratio (HR), and 95% confidence interval (CI) as effect values.

resultsFourteen studies containing 2,106 patients with GC were analyzed. The overall analysis showed that CLDN4 expression was associated with increasing pT category, tumor size, and lymph node metastasis in patients with GC (pT3-T4 vs pT1-T2: OR =1.56, 95% CI =1.13-2.16; P<0.01; large tumor size vs small tumor size: OR =1.64, 95% CI =1.15-2.34; P<0.01; positive lymph node metastasis vs negative lymph node metastasis: OR =1.49, 95% CI =1.12-1.97; P<0.01). CLDN4 expression was associated with histological differentiation (differentiated type vs undifferentiated type: OR =2.90, 95% CI =1.32-6.37; P=0.01; Lauren intestinal type vs diffuse type: OR =3.51, 95% CI =1.48-8.28; P<0.01). CLDN4 expression was also strongly associated with sex and age. This meta-analysis found no significant association between CLDN4 expression and prognosis for overall survival in patients with GC (HR =0.74, 95% CI =0.43-1.27; P=0.28).

conclusionPresent study indicates that aberrant CLDN4 expression plays an important role in the clinicopathological characteristics of GC.

Indexed as

biomarkerCLDN4gastric cancermeta-analysismetastasisprognosisstage

Identifiers

PMID27313466
PMCPMC4892849
OpenAlexW2395407741

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.